News
A new clinical trial has revealed that tirzepatide (Zepbound) surpasses semaglutide (Wegovy) in promoting weight loss among ...
A study, which was published in The New England Journal of Medicine, found that tirzepatide (Zepbound) is more effective for ...
Early-stage study results suggest that a single shot of the company’s therapy, which works differently than GLP-1 medicines, ...
7h
News-Medical.Net on MSNReal-world study finds lower weight loss with GLP-1 drugs due to early discontinuationA Cleveland Clinic study shows that semaglutide and tirzepatide – injectable GLP-1 drugs for obesity – produce smaller weight ...
American teens are increasingly turning to the weight-loss drug Wegovy as more families and their doctors gain confidence in ...
Viking Therapeutics faces tough obesity drug rivals, with VK2735 showing promise but an uncertain edge. Find out why VKTX ...
3. In a head-to-head trial, Eli Lilly’s weight loss drug Zepbound led to more weight loss than Novo Nordisk’s Wegovy. At the end of the 72-week study, patients taking Zepbound lost an average 20.2% of ...
I've been a Novo Nordisk bull for quite some time now, and I wouldn't be as spooked by the situation. Here's why. Novo Nordisk got a two-year-plus head start in the white-hot obesity drugs market, ...
Veru reports strong safety and efficacy for enobosarm added to semaglutide, showing reduced functional decline and muscle ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results